Long-term study confirms DUVYZAT clinical trial results
After the initial clinical trial, researchers have continued to track participants in the study. This study is still ongoing, but the information shown includes results collected from October 2017 to December 2021.
The long-term study included 194 participants with Duchenne, all aged 6 years or older
All of the participants were taking DUVYZAT + steroids for over 18 months.
The long-term study included 194 participants with Duchenne, all aged 6 years or older
All of the participants were taking DUVYZAT + steroids for over 18 months.
MAIN MEASURE
Long-term safety results with DUVYZAT
The main measure of the long-term study was to better understand the safety of DUVYZAT over an extended period of time.
-
Side effects in the long-term study were similar to those in the prior clinical trial
-
87% of participants experienced side effects; most were mild or moderate in severity
-
Serious side effects occurred in 12% of participants, though none were fatal or life threatening
Continued observations with DUVYZAT
In the ongoing study, researchers also looked at how long participants taking DUVYZAT + steroids were likely to maintain their muscle strength and ability to walk. These results were compared with information from people with Duchenne who were treated with steroids but did not receive DUVYZAT.
Results suggest that participants taking DUVYZAT + steroids may maintain:
Ability to walk for
2.9 years longer*
Ability to rise from
the floor for
2.0 years longer*
Ability to climb
4 stairs for
3.3 years longer*
Key Safety Information